|
[1]
|
Jha, V., Garcia-Garcia, G., Iseki, K., et al. (2013) Chronic Kidney Disease: Global Dimension and Perspectives [Published Correction Appears in Lancet. 2013 Jul 20; 382(9888): 208]. The Lancet, 382, 260-272.
[Google Scholar] [CrossRef]
|
|
[2]
|
中国医师协会肾脏内科医师分会肾性贫血指南工作组. 中国肾性贫血诊治临床实践指南[J]. 中华医学杂志, 2021, 101(20): 1463-1502.
|
|
[3]
|
Ogawa, C., Tsuchiya, K., Maeda, K. and Nitta, K. (2018) Renal Anemia and Iron Metabolism. Contributions to Nephrology, 195, 62-73.
[Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
KDOQI, National Kidney Foundation (2006) KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease [Published Correction Appears in Am J Kidney Dis. 2006 Sep; 48(3): 518]. American Journal of Kidney Diseases, 47, S11-S145.
|
|
[5]
|
Gafter-Gvili, A., Schechter, A. and Rozen-Zvi, B. (2019) Iron Deficiency Anemia in Chronic Kidney Disease. Acta Haematologica, 142, 44-50.
[Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Ratcliffe, L.E., Thomas, W., Glen, J., et al. (2016) Diagnosis and Management of Iron Deficiency in CKD: A Summary of the NICE Guideline Recommendations and Their Rationale. American Journal of Kidney Diseases, 67, 548-558.
[Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Ganz, T. and Nemeth, E. (2012) Hepcidin and Iron Homeostasis. Biochimica et Biophysica Acta, 1823, 1434-1443.
[Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Krause, A., Neitz, S., Mägert, H.J., et al. (2000) LEAP-1, a Novel Highly Disulfide-Bonded Human Peptide, Exhibits Antimicrobial Activity. FEBS Letters, 480, 147-150.
[Google Scholar] [CrossRef]
|
|
[9]
|
Park, C.H., Valore, E.V., Waring, A.J. and Ganz, T. (2001) Hepcidin, a Urinary Antimicrobial Peptide Synthesized in the Liver. Journal of Biological Chemistry, 276, 7806-7810.
[Google Scholar] [CrossRef]
|
|
[10]
|
Hunter, H.N., Fulton, D.B., Ganz, T. and Vogel, H.J. (2002) The Solution Structure of Human Hepcidin, a Peptide Hormone with Antimicrobial Activity That Is Involved in Iron Uptake and Hereditary Hemochromatosis. Journal of Biological Chemistry, 277, 37597-37603.
[Google Scholar] [CrossRef]
|
|
[11]
|
Zhang, D.L. and Rouault, T.A. (2018) How Does Hepcidin Hinder Ferroportin Activity? Blood, 131, 840-842.
[Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Ueda, N. and Takasawa, K. (2017) Role of Hepcidin-25 in Chronic Kidney Disease: Anemia and Beyond. Current Medicinal Chemistry, 24, 1417-1452.
[Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Core, A.B., Canali, S. and Babitt, J.L. (2014) Hemojuvelin and Bone Morphogenetic Protein (BMP) Signaling in Iron Homeostasis. Frontiers in Pharmacology, 5, Article No. 104.
[Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Uehata, T., Tomosugi, N., Shoji, T., et al. (2012) Serum Hepcidin-25 Levels and Anemia in Non-Dialysis Chronic Kidney Disease Patients: A Cross-Sectional Study. Nephrology Dialysis Transplantation, 27, 1076-1083.
[Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Rodriguez, R., Jung, C.L., Gabayan, V., et al. (2014) Hepcidin Induction by Pathogens and Pathogen-Derived Molecules Is Strongly Dependent on Interleukin-6. Infection and Immunity, 82, 745-752.
[Google Scholar] [CrossRef]
|
|
[16]
|
Łukaszyk, E., Łukaszyk, M., Koc-Żórawska, E., et al. (2015) Iron Status and Inflammation in Early Stages of Chronic Kidney Disease. Kidney and Blood Pressure Research, 40, 366-373.
[Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Nemeth, E., Rivera, S., Gabayan, V., et al. (2004) IL-6 Mediates Hypoferremia of Inflammation by Inducing the Synthesis of the Iron Regulatory Hormone Hepcidin. Journal of Clinical Investigation, 113, 1271-1276.
[Google Scholar] [CrossRef]
|
|
[18]
|
Nai, A., Rubio, A., Campanella, A., et al. (2016) Limiting Hepatic Bmp-Smad Signaling by Matriptase-2 Is Required for Erythropoietin-Mediated Hepcidin Suppression in Mice. Blood, 127, 2327-2336.
[Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Shanmugam, N.K., Chen, K. and Cherayil, B.J. (2015) Commensal Bacteria-Induced Interleukin 1β (IL-1β) Secreted by Macrophages Up-Regulates Hepcidin Expression in Hepatocytes by Activating the Bone Morphogenetic Protein Signaling Pathway. Journal of Biological Chemistry, 290, 30637-30647.
[Google Scholar] [CrossRef]
|
|
[20]
|
Ueda, N. and Takasawa, K. (2018) Impact of Inflammation on Ferritin, Hepcidin and the Management of Iron Deficiency Anemia in Chronic Kidney Disease. Nutrients, 10, 1173.
[Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Shoji, S., Inaba, M., Tomosugi, N., et al. (2013) Greater Potency of Darbepoetin-α than Erythropoietin in Suppression of Serum Hepcidin-25 and Utilization of Iron for Erythropoiesis in Hemodialysis Patients. European Journal of Haematology, 90, 237-244.
[Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Swinkels, D.W., Girelli, D., Laarakkers, C., et al. (2008) Advances in Quantitative Hepcidin Measurements by Time-of-Flight Mass Spectrometry. PLoS ONE, 3, e2706.
[Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Troutt, J.S., Butterfield, A.M. and Konrad, R.J. (2013) Hepcidin-25 Concentrations Are Markedly Increased in Patients with Chronic Kidney Disease and Are Inversely Correlated with Estimated Glomerular Filtration Rates. Journal of Clinical Laboratory Analysis, 27, 504-510.
[Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Nicolas, G., Chauvet, C., Viatte, L., et al. (2002) The Gene Encoding the Iron Regulatory Peptide Hepcidin Is Regulated by Anemia, Hypoxia, and Inflammation. Journal of Clinical Investigation, 110, 1037-1044.
[Google Scholar] [CrossRef]
|
|
[25]
|
Semenza, G.L. (2000) HIF-1: Mediator of Physiological and Pathophysiological Responses to Hypoxia. Journal of Applied Physiology (1985), 88, 1474-1480.
[Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Liu, Q., Davidoff, O., Niss, K. and Haase, V.H. (2012) Hypoxia-Inducible Factor Regulates Hepcidin via Erythropoietin-Induced Erythropoiesis. Journal of Clinical Investigation, 122, 4635-4644.
[Google Scholar] [CrossRef]
|
|
[27]
|
Pasricha, S.R., McHugh, K. and Drakesmith, H. (2016) Regulation of Hepcidin by Erythropoiesis: The Story So Far. Annual Review of Nutrition, 36, 417-434.
[Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Kautz, L., Jung, G., Valore, E.V., Rivella, S., Nemeth, E. and Ganz, T. (2014) Identification of Erythroferrone as an Erythroid Regulator of Iron Metabolism [Published Correction Appears in Nat Genet. 2020 Apr; 52(4): 463]. Nature Genetics, 46, 678-684.
[Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Bacchetta, J., Zaritsky, J.J., Sea, J.L., et al. (2014) Suppression of Iron-Regulatory Hepcidin by Vitamin D. Journal of the American Society of Nephrology, 25, 564-572.
[Google Scholar] [CrossRef]
|
|
[30]
|
Schödel, J. and Ratcliffe, P.J. (2019) Mechanisms of Hypoxia Signalling: New Implications for Nephrology. Nature Reviews Nephrology, 15, 641-659.
[Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Haase, V.H. (2017) HIF-Prolyl Hydroxylases as Therapeutic Targets in Erythropoiesis and Iron Metabolism. Hemodialysis International, 21, S110-S124.
[Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Bruick, R.K. and McKnight, S.L. (2001) A Conserved Family of Prolyl-4-hydroxylases That Modify HIF. Science, 294, 1337-1340.
[Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Dhillon, S. (2019) Roxadustat: First Global Approval. Drugs, 79, 563-572.
[Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Barratt, J., Sulowicz, W., Schömig, M., et al. (2021) Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies. Advances in Therapy, 38, 5345-5360.
[Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Akizawa, T., Iwasaki, M., Otsuka, T., Yamaguchi, Y. and Reusch, M. (2021) Phase 3 Study of Roxadustat to Treat Anemia in Non-Dialysis-Dependant CKD. Kidney International Reports, 6, 1810-1828.
[Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Wish, J.B., Eckardt, K.U., Kovesdy, C.P., Fishbane, S., Spinowitz, B.S. and Berns, J.S. (2021) Hypoxia-Inducible Factor Stabilization as an Emerging Therapy for CKD-Related Anemia: Report from a Scientific Workshop Sponsored by the National Kidney Foundation. American Journal of Kidney Diseases, 78, 709-718.
[Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Dhillon, S. (2020) Daprodustat: First Approval. Drugs, 80, 1491-1497.
[Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Markham, A. (2020) Vadadustat: First Approval. Drugs, 80, 1365-1371.
[Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Markham, A. (2021) Enarodustat: First Approval. Drugs, 81, 169-174.
[Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Singh, A.K., Carroll, K., Perkovic, V., et al. (2021) Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. The New England Journal of Medicine, 385, 2325-2335.
[Google Scholar] [CrossRef]
|
|
[41]
|
Singh, A.K., Carroll, K., McMurray, J.J.V., et al. (2021) Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. The New England Journal of Medicine, 385, 2313-2324.
[Google Scholar] [CrossRef]
|
|
[42]
|
Akizawa, T., Nobori, K., Matsuda, Y., et al. (2021) Molidustat for the Treatment of Anemia in Japanese Patients Undergoing Peritoneal Dialysis: A Single-Arm, Open-Label, Phase 3 Study [Published Online Ahead of Print, 2021 Jul 26]. Therapeutic Apheresis and Dialysis.
[Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Akizawa, T., Yamada, T., Nobori, K., et al. (2021) Molidustat for Japanese Patients with Renal Anemia Receiving Dialysis. Kidney International Reports, 6, 2604-2616.
[Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Yap, D.Y.H., McMahon, L.P., Hao, C.M., et al. (2021) Recommendations by the Asian Pacific Society of Nephrology (APSN) on the Appropriate Use of HIF-PH Inhibitors. Nephrology (Carlton), 26, 105-118.
[Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Locatelli, F., Del Vecchio, L. and Luise, M.C. (2017) Current and Future Chemical Therapies for Treating Anaemia in Chronic Kidney Disease. Expert Opinion on Pharmacotherapy, 18, 781-788.
[Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Jelkmann, W. (2018) Activin Receptor Ligand Traps in Chronic Kidney Disease. Current Opinion in Nephrology and Hypertension, 27, 351-357.
[Google Scholar] [CrossRef]
|